Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Cancer Biol. 2006 Dec;16(6):436-43. Epub 2006 Sep 26.

Thioredoxin in cancer--role of histone deacetylase inhibitors.

Author information

1
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. PaulA@Marks.org

Abstract

Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi.

PMID:
17095247
PMCID:
PMC2766865
DOI:
10.1016/j.semcancer.2006.09.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center